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Abstract
The Retrovirology Open Access experience after publishing more than 500 articles is discussed.
Editorial
As 2009 comes to a close, it is instructive to reflect upon
Retrovirology's  experience with Open Access publishing.
The journal was started with two objectives. First, there
was a recognition that the robust field of basic retrovirus
research could benefit from a dedicated rapid-publication
online journal of good quality. Second, there was a desire
to build a journal that would be freely accessible in full
text to all readers without being restricted by the ability to
pay for a subscription.
Retrovirology launched in February 2004 and since then
has published more than 550 papers. To maintain a high
scientific standard, the journal aims to have no more than
10 articles per month or roughly a total of 120 per year.
From 2005 through 2009, Retrovirology has averaged ~100
published items per year (Figure 1). The quality of the
journal has been monitored stringently by the editors and
the editorial board and has improved over time. The latter
assertion is supported by several observations. For
instance, in November 2004, Retrovirology received 6 sub-
missions and published 5 papers that month. By contrast,
in November 2008, Retrovirology received 27 submissions
and published 10 papers; and in November 2009, the
journal received 29 submissions and published 10. In par-
allel, the rate of annual citations to Retrovirology has also
increased steadily with a healthy upslope (Figure 1).
Open Access publishing in 2004 was viewed skeptically as
a new approach with an uncertain future. In the begin-
ning, many colleagues openly questioned whether an
Open Access Retrovirology journal could be successful. Five
years later, most subscription-based journals now offer
their authors an Open Access option, and Retrovirology, as
measured by SCImago journal rating http://www.scima
gojr.com/ using data from Scopus, ranks in the top quar-
tile of all virology journals. Similarly in data from the
Journal Citation Reports of the ISI http://pcs.isiknowl
edge.com,  Retrovirology  has a recent Impact Factor [1]
which is closely behind that of the Journal of Virology, and
ahead of Virology, the Journal of General Virology, and AIDS
Research and Human Retroviruses. The visibility of Retrovi-
rology  papers is attested by the citation numbers to
recently published papers. For example, two Retrovirology
review articles [2,3] published in 2007 and 2008 have
already been cited 54 and 33 times, while two 2007
research papers [4,5] have been cited 27 and 23 times.
These numbers are competitive with the citation frequen-
cies to articles of similar age and similar topics published
in other highly rated journals.
Periodically, emails arrive to me from colleagues in South
America and graduate students in Africa conveying thanks
for Retrovirology's fee-free full text Open Access format. As
the journal's editor-in-chief, I am gratified by these
responses. Perhaps on occasions when you are delayed in
an airport lounge and need to read the full text of retrovi-
rology papers using your personal lap top computer, you
might be similarly gratified that Retrovirology  is Open
Access. The Retrovirology Open Access experience has been
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good for science, good for authors, and good for readers.
The journal is doing well by doing good.
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